Often associated with unmutated IGHV status and bulky disease, del(11q), combined with TP53 alterations, leads to highly adverse outcomes in CLL patients, promoting a clonal advantage in vitro and in vivo [9]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.